Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06785194 · ClinicalTrials.gov registry record
Revive Toric RWE Study
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Not yet
- Registry status
- 30
- Enrollment target
NCT06785194: Clinical Trial study, sponsored by Bausch & Lomb Incorporated.
NCT06785194 is a clinical trial that has not yet begun recruiting, run by Bausch & Lomb Incorporated. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06785194 has not yet begun recruiting, sponsored by Bausch & Lomb Incorporated.
- NOT YET RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
This is a post-market observational clinical investigation. The objective of this observational study is to evaluate the visual performance and HCP satisfaction of REVIVE samfilcon B custom toric contact lenses.
Primary Outcome
(completed by the Investigator for each subject at 14 days ± 3 days after the final dispensing/refinement visit)
Interventions
- DEVICE REVIVE samfilcon B custom toric contact lenses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05 |
| Est. Completion | 2026-07 |
What is known before NCT06785194 opens enrollment
NCT06785194 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which REVIVE samfilcon B custom toric contact lenses is the first listed.
NCT06785194 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06785194 about?
NCT06785194 is a clinical study titled "Revive Toric RWE Study". This is a post-market observational clinical investigation. The objective of this observational study is to evaluate the visual performance and HCP satisfaction of REVIVE samfilcon B custom toric contact lenses.
What is the current status of trial NCT06785194?
This trial is currently not yet recruiting. The enrollment target is 30 participants. The study started on 2026-05. Estimated completion is 2026-07.
What interventions are being tested in trial NCT06785194?
The interventions under investigation include: REVIVE samfilcon B custom toric contact lenses (DEVICE).
Who is sponsoring clinical trial NCT06785194?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia